The Addition of Atezolizumab to Chemotherapy in Non-Small Cell Lung Cancer: A Trial-Based Review and Meta-Analysis.
Nadya Keumala FitriBahagia Willibrordus Maria NainggolanNaufal Nandita FirstyAndika PradanaDina Keumala SariPublished in: World journal of oncology (2023)
Upon examination, the study reveals that the addition of atezolizumab demonstrates notable improvements in both OS and PFS among NSCLC patients. These findings present promising attributes for atezolizumab as a viable treatment for NSCLC. However, it is important to acknowledge that the future holds further revelations in this realm, and more insights are yet to be uncovered.
Keyphrases
- small cell lung cancer
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- advanced non small cell lung cancer
- clinical trial
- prognostic factors
- study protocol
- randomized controlled trial
- peritoneal dialysis
- current status
- locally advanced
- open label
- brain metastases
- replacement therapy